Product Introduction:
Azacamen 100mg contains Azacitidine, a pyrimidine nucleoside analog classified as a hypomethylating agent. It is used to treat bone marrow disorders and certain blood cancers by interfering with the growth of abnormal cells and encouraging the formation of healthy blood cells. It is administered via injection under the skin or into a vein, usually in a clinical setting.
Uses:
Azacamen 100mg is used in the treatment of:
-
Myelodysplastic syndromes (MDS)
-
Chronic myelomonocytic leukemia (CMML)
-
Acute myeloid leukemia (AML) in elderly or unfit patients
-
Bone marrow failure syndromes
-
Off-label in combination with other agents for AML
-
Prevention of disease progression to acute leukemia from MDS
Storage Instructions:
-
Store at 2°C to 8°C (Refrigerated)
-
After reconstitution, use immediately or store as per label (usually within 1 hour)
-
Protect from light and moisture
-
Do not freeze
-
Keep out of reach of children
How It Works (Mechanism of Action):
Azacitidine works by inhibiting DNA methylation, an epigenetic process that silences tumor suppressor genes. It incorporates into DNA and RNA of rapidly dividing abnormal cells, leading to cell cycle arrest, apoptosis (cell death), and differentiation. This reduces the proliferation of abnormal blood cells and allows normal cell production to resume in the bone marrow.
Side Effects:
Common side effects:
-
Nausea and vomiting
-
Injection site pain or redness
-
Fatigue
-
Constipation or diarrhea
-
Loss of appetite
Severe side effects:
-
Bone marrow suppression (anemia, neutropenia, thrombocytopenia)
-
Infections (fever, chills, sore throat)
-
Liver toxicity
-
Kidney dysfunction
-
Bleeding or bruising easily
-
Allergic reactions or anaphylaxis (rare)
Dosage (Typical Recommended Dose):
-
Standard dose: 75 mg/m² once daily for 7 consecutive days every 28-day cycle
-
The number of cycles depends on clinical response, often continued for 6 or more cycles
-
Dosage may be adjusted based on blood counts and side effects
Method of Administration:
-
Can be administered subcutaneously (under the skin) or intravenously (IV)
-
Given by a healthcare professional
-
Reconstitution required before administration
-
Adequate hydration and antiemetic support are usually provided before dosing
Precautions:
-
Monitor complete blood counts regularly
-
Use caution in patients with liver or kidney impairment
-
Not recommended during pregnancy or breastfeeding – may cause fetal harm
-
May require dose modification or delay based on toxicity
-
Patients should avoid contact with people who have infections
Drug Interactions:
-
Use cautiously with other myelosuppressive agents
-
Possible interaction with nephrotoxic or hepatotoxic drugs
-
No major CYP450 metabolism – limited drug-drug interaction, but monitor closely
Allergies:
-
Avoid in patients with known hypersensitivity to Azacitidine or mannitol
-
Watch for signs of anaphylaxis: rash, difficulty breathing, swelling
Overdose Information:
-
Overdose can cause severe bone marrow suppression, infections, bleeding
-
No specific antidote; manage with supportive care and monitor closely
-
Hospitalization may be required in severe overdose
Missed Dose Instructions:
-
If a dose is missed, consult the doctor or healthcare team immediately
-
Do not take extra doses to make up for a missed one
-
Resume treatment as per physician’s guidance
Additional Notes:
-
Patients should be educated about infection prevention and when to seek medical help
-
Birth control is advised during treatment and for a period after completion
-
Treatment is most effective when continued over multiple cycles
-
Bone marrow monitoring is essential to determine effectiveness and safety
Product Introduction:
Azacamen 100mg contains Azacitidine, a pyrimidine nucleoside analog classified as a hypomethylating agent. It is used to treat bone marrow disorders and certain blood cancers by interfering with the growth of abnormal cells and encouraging the formation of healthy blood cells. It is administered via injection under the skin or into a vein, usually in a clinical setting.
Uses:
Azacamen 100mg is used in the treatment of:
-
Myelodysplastic syndromes (MDS)
-
Chronic myelomonocytic leukemia (CMML)
-
Acute myeloid leukemia (AML) in elderly or unfit patients
-
Bone marrow failure syndromes
-
Off-label in combination with other agents for AML
-
Prevention of disease progression to acute leukemia from MDS
Storage Instructions:
-
Store at 2°C to 8°C (Refrigerated)
-
After reconstitution, use immediately or store as per label (usually within 1 hour)
-
Protect from light and moisture
-
Do not freeze
-
Keep out of reach of children
How It Works (Mechanism of Action):
Azacitidine works by inhibiting DNA methylation, an epigenetic process that silences tumor suppressor genes. It incorporates into DNA and RNA of rapidly dividing abnormal cells, leading to cell cycle arrest, apoptosis (cell death), and differentiation. This reduces the proliferation of abnormal blood cells and allows normal cell production to resume in the bone marrow.
Side Effects:
Common side effects:
-
Nausea and vomiting
-
Injection site pain or redness
-
Fatigue
-
Constipation or diarrhea
-
Loss of appetite
Severe side effects:
-
Bone marrow suppression (anemia, neutropenia, thrombocytopenia)
-
Infections (fever, chills, sore throat)
-
Liver toxicity
-
Kidney dysfunction
-
Bleeding or bruising easily
-
Allergic reactions or anaphylaxis (rare)
Dosage (Typical Recommended Dose):
-
Standard dose: 75 mg/m² once daily for 7 consecutive days every 28-day cycle
-
The number of cycles depends on clinical response, often continued for 6 or more cycles
-
Dosage may be adjusted based on blood counts and side effects
Method of Administration:
-
Can be administered subcutaneously (under the skin) or intravenously (IV)
-
Given by a healthcare professional
-
Reconstitution required before administration
-
Adequate hydration and antiemetic support are usually provided before dosing
Precautions:
-
Monitor complete blood counts regularly
-
Use caution in patients with liver or kidney impairment
-
Not recommended during pregnancy or breastfeeding – may cause fetal harm
-
May require dose modification or delay based on toxicity
-
Patients should avoid contact with people who have infections
Drug Interactions:
-
Use cautiously with other myelosuppressive agents
-
Possible interaction with nephrotoxic or hepatotoxic drugs
-
No major CYP450 metabolism – limited drug-drug interaction, but monitor closely
Allergies:
-
Avoid in patients with known hypersensitivity to Azacitidine or mannitol
-
Watch for signs of anaphylaxis: rash, difficulty breathing, swelling
Overdose Information:
-
Overdose can cause severe bone marrow suppression, infections, bleeding
-
No specific antidote; manage with supportive care and monitor closely
-
Hospitalization may be required in severe overdose
Missed Dose Instructions:
-
If a dose is missed, consult the doctor or healthcare team immediately
-
Do not take extra doses to make up for a missed one
-
Resume treatment as per physician’s guidance
Additional Notes:
-
Patients should be educated about infection prevention and when to seek medical help
-
Birth control is advised during treatment and for a period after completion
-
Treatment is most effective when continued over multiple cycles
-
Bone marrow monitoring is essential to determine effectiveness and safety
